publication . Article . 2009

Alzheimer's disease therapeutic research: the path forward

Paul S Aisen;
Open Access English
  • Published: 01 Jul 2009 Journal: Alzheimer's Research & Therapy, volume 1, issue 1, pages 2-2 (eissn: 1758-9193, Copyright policy)
  • Publisher: BioMed Central
The field of Alzheimer's disease therapeutic research seems poised to bring to clinic the next generation of treatments, moving beyond symptomatic benefits to modification of the underlying neurobiology of the disease. But a series of recent trials has had disappointingly negative results that raise questions about our drug development strategies. Consideration of ongoing programs demonstrates difficult pitfalls. But a clear path forward is emerging. Successful strategies will utilize newly available tools to reconsider issues of diagnosis, assessment and analysis, facilitating the study of new treatments at early stages in the disease process at which they are ...
free text keywords: Commentary, Cognitive Neuroscience, Neurology, Clinical Neurology, Down syndrome, medicine.disease, medicine, Geriatric psychiatry, Disease process, business.industry, business, Psychiatry, medicine.medical_specialty, Alternative medicine, Drug development, Disease
Funded by
NIH| Alzheimers Disease Neuroimaging Initiative
  • Funder: National Institutes of Health (NIH)
  • Project Code: 1U01AG024904-01
  • Funder: National Institutes of Health (NIH)
  • Project Code: 5U01AG010483-07
34 references, page 1 of 3

Katzman, R. Editorial: The prevalence and malignancy of Alzheimer disease. A major killer. Arch Neurol. 1976; 33: 217-218 [OpenAIRE] [PubMed]

Vellas, B, Coley, N, Andrieu, S. Disease modifying trials in Alzheimer's disease: perspectives for the future. J Alzheimers Dis. 2008; 15: 289-301 [OpenAIRE] [PubMed]

Hardy, J, Selkoe, DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002; 297: 353-356 [OpenAIRE] [PubMed] [DOI]

Schmidt, AM, Yan, SD, Yan, SF, Stern, DM. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000; 1498: 99-111 [PubMed] [DOI]

Yan, SD, Chen, X, Fu, J, Chen, M, Zhu, HJ, Roher, A, Slattery, T, Zhao, L, Nagashima, M, Morser, J, Migheli, A, Nawroth, P, Stern, D, Schmidt, AM. RAGE and amyloid-Beta peptide neurotoxicity in Alzheimer's disease. Nature. 1996; 382: 685-691 [OpenAIRE] [PubMed] [DOI]

Lauren, J, Gimbel, DA, Nygaard, HB, Gilbert, JW, Strittmatter, SM. Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. Nature. 2009; 457: 1128-1132 [OpenAIRE] [PubMed] [DOI]

Avila, J, Hernandez, F. GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother. 2007; 7: 1527-1533 [OpenAIRE] [PubMed] [DOI]

Tuszynski, MH, Thal, L, Pay, M, Salmon, DP, U, HS, Bakay, R, Patel, P, Blesch, A, Vahlsing, HL, Ho, G, Tong, G, Potkin, SG, Fallon, J, Hansen, L, Mufson, EJ, Kordower, JH, Gall, C, Conner, J. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005; 11: 551-555 [OpenAIRE] [PubMed] [DOI]

Gervais, F, Paquette, J, Morissette, C, Krzywkowski, P, Yu, M, Azzi, M, Lacombe, D, Kong, X, Aman, A, Laurin, J, Szarek, WA, Tremblay, P. Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis. Neurobiol Aging. 2007; 28: 537-547 [OpenAIRE] [PubMed] [DOI]

Aisen, PS, Saumier, D, Briand, R, Laurin, J, Gervais, F, Tremblay, P, Garceau, D. A phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology. 2006; 67: 1757-1763 [OpenAIRE] [PubMed] [DOI]

Weggen, S, Eriksen, JL, Das, P, Sagi, SA, Wang, R, Pietrzik, CU, Findlay, KA, Smith, TE, Murphy, MP, Bulter, T, Kang, DE, Marquez-Sterling, N, Golde, TE, Koo, EH. A subset of NSAIDs lower amy-loidogenic Abeta42 independently of cyclooxygenase activity. Nature. 2001; 414: 212-216 [OpenAIRE] [PubMed] [DOI]

Kukar, T, Prescott, S, Eriksen, JL, Holloway, V, Murphy, MP, Koo, EH, Golde, TE, Nicolle, MM. Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. BMC Neurosci. 2007; 8: 54 [OpenAIRE] [PubMed] [DOI]

Wilcock, GK, Black, SE, Hendrix, SB, Zavitz, KH, Swabb, EA, Laughlin, MA. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 2008; 7: 483-493 [OpenAIRE] [PubMed] [DOI]

Relkin, NR. Current state of immunotherapy for Alzheimer's disease. CNS Spectr. 2008; 13: 39-41 [PubMed]

Alzheimer's Disease Neuroimaging Initiative.

34 references, page 1 of 3
Powered by OpenAIRE Research Graph
Any information missing or wrong?Report an Issue